iCAD, Inc. (NASDAQ:ICAD) Q4 2020 Earnings Conference Call February 24, 2021 4:30 PM ET Company Participants Jeremy Feffer – LifeSci Advisors, LLC Michael Klein – Chairman and Chief Executive Officer Scott Areglado – Chief Financial Officer Stacey Stevens – President Conference Call Participants Kyle Mikson – Cantor Fitzgerald Frank Takkinen – Lake Street Capital Markets Per Erik Ostlund – Craig-Hallum Dave Turkaly – JMP Securities Gene Mannheimer – Dougherty & Company Andrew DeSilva – B. Riley Securities Op ...

iCAD, Inc. (NASDAQ:ICAD) Q3 2020 Earnings Conference Call November 5, 2020 4:30 PM ET Company Participants Jeremy Feffer - Investor Relations Michael Klein - Chairman and Chief Executive Officer Stacey Stevens - President Scott Areglado - Chief Financial Officer Conference Call Participants Dave Turkaly - JMP Securities Gene Mannheimer - Collier Securities Per Ostlund - Craig-Hallum Capital Group Operator Greetings and welcome to the iCAD, Inc. Third Quarter 2020 Earnings Conference Call. [Operator Instruct ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-09341 iCAD, Inc. (Exact name of registrant as specified in its charter) Delaware 02-0377419 (State or othe ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-09341 iCAD, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorpo ...

| --- | --- | --- | --- | --- | --- | --- | --- | |-------------------------------------------|-------|-------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | iCAD Corporate Presentation NASDAQ: ICAD | | | | | | | | Safe Harbor Statement Certain statements contained in this presentation constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, ...

iCAD, Inc. (NASDAQ:ICAD) Q2 2020 Earnings Conference Call August 4, 2020 4:30 PM ET Company Participants Jeremy Feffer - LifeSci Advisors Michael Klein - Chairman and Chief Executive Officer Scott Areglado - Chief Financial Officer Stacey Stevens - President Conference Call Participants Dave Turkaly - JMP Securities Per Ostlund - Craig-Hallum Brooks O'Neil - Lake Street Capital Markets Operator Greetings and welcome to the iCAD, Incorporated. Second Quarter 2020 Earnings Call. At this time all participants ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to iCAD, Inc. (Exact name of registrant as specified in its charter) Delaware 02-0377419 (State or other jurisdiction of incorporation or or ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to _ Commission file number 001-09341 iCAD, INC. (Exact name of registrant as specified in its charter) Delaware 02-0377419 (State or other juris ...

| --- | --- | --- | --- | --- | --- | --- | |-------------------------------------------|-------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | iCAD Corporate Presentation NASDAQ: ICAD | | | | | | | Safe Harbor Statement Certain statements contained in this presentation constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, unce ...

Financial Data and Key Metrics Changes - Total revenue for Q4 2019 was $9.4 million, an increase of $2.4 million or 35% compared to Q4 2018 [33] - AI business revenue grew by $1.9 million or 39% to $6.9 million compared to $4.9 million in Q4 2018 [34] - GAAP net loss for Q4 was $3.3 million or $0.17 per share, compared to a net loss of $3.3 million or $0.20 per share in Q4 2018 [39] Business Line Data and Key Metrics Changes - Detection business revenue grew 39% in Q4 2019 compared to Q4 2018, with software license sales increasing 59% year-over-year [7] - Direct sales in the detection business increased by 87% in 2019 compared to 2018, accounting for approximately 60% of overall revenue in the AI business [35] - Xoft radiation therapy business revenues were up 3% for the full year, with Q4 revenues doubling compared to Q3 [21] Market Data and Key Metrics Changes - The U.S. market remains a significant driver for overall revenue, primarily through 3D sales [35] - Over 9,000 3D systems are installed in the U.S., with an additional 1,000 units in Europe, presenting robust sales opportunities [12] - The company has established a stronger direct presence in Europe, increasing coverage to 19 countries [47] Company Strategy and Development Direction - The company aims to drive towards risk-adaptive screening, with the introduction of ProFound Panorama technology [15] - A focus on improving clinical outcomes, patient satisfaction, and clinician experience while reducing overall healthcare costs aligns with the Institute for Healthcare Improvement's Triple Aim initiative [43] - The company is actively engaging with large integrated delivery networks and group purchasing organizations to accelerate revenue growth [45] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the momentum built during 2019 and anticipates continued success in 2020 [41] - The introduction of new technologies and clinical data is expected to enhance the adoption of Xoft and ProFound AI [42] - The company is optimistic about the potential impact of bundled payment models on the IORT business [86] Other Important Information - The company executed a forced conversion of convertible debentures, eliminating $13.6 million of debt and strengthening its financial position [40] - A new board member, Nathaniel Dalton, was welcomed, bringing extensive experience in capital markets and public companies [32] Q&A Session All Questions and Answers Question: Regarding the $1.8 million order, how many facilities does it cover and what is the pipeline for similar opportunities? - Management noted that healthcare systems are increasingly acquiring core technology and that there are opportunities for larger deals in the pipeline [60][61] Question: Are the accounts using CAD new customers or existing ones? - Approximately 80% to 85% of the market is already using CAD, with opportunities to upgrade existing installations and convert accounts not currently using CAD [63][64] Question: What is the timeline for the launch of Panorama and the awareness among existing ProFound AI users? - The launch of ProFound Panorama is planned for the second half of the year, starting in Europe, with a focus on 2D before moving to the U.S. [73][75] Question: What is the status of the bundled payment model and its potential impact? - There is no formal update, but expectations point towards a spring release of final language, which could accelerate business growth [85][86] Question: How does the company view its competitive position in the AI space? - The company believes it has a significant advantage due to its extensive data collection from 7,000 sites and FDA clearance for 3D AI, positioning it ahead of potential competitors [94][96]